Heinrich, Elmar

[["dc.bibliographiccitation.firstpage","627"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.lastpage","633"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","von Hardenberg, Jost"],["dc.contributor.author","Worst, Thomas S."],["dc.contributor.author","Westhoff, Niklas"],["dc.contributor.author","Erben, Philipp"],["dc.contributor.author","Fuxius, Stefan"],["dc.contributor.author","Müller, Markus"],["dc.contributor.author","Bolenz, Christian"],["dc.contributor.author","Weiss, Christel"],["dc.contributor.author","Heinrich, Elmar"],["dc.date.accessioned","2020-12-10T18:37:50Z"],["dc.date.available","2020-12-10T18:37:50Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1159/000490618"],["dc.identifier.eissn","2296-5262"],["dc.identifier.issn","2296-5270"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77109"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","201"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Urologia Internationalis"],["dc.bibliographiccitation.lastpage","206"],["dc.bibliographiccitation.volume","99"],["dc.contributor.author","Martinschek, Andreas"],["dc.contributor.author","Stumm, Lisa"],["dc.contributor.author","Ritter, Manuel"],["dc.contributor.author","Heinrich, Elmar"],["dc.contributor.author","Bolenz, Christian"],["dc.contributor.author","Trojan, Lutz"],["dc.date.accessioned","2020-12-10T18:37:48Z"],["dc.date.available","2020-12-10T18:37:48Z"],["dc.date.issued","2017"],["dc.description.abstract","Objectives: To evaluate in a prospective, controlled, nonrandomized study the surgical stress and acute-phase systemic response in robotic-assisted laparoscopic prostatectomy (RALP) compared to open radical retro-pubic prostatectomy (ORRP) by measuring humoral mediators. Methods: Forty consecutive patients undergoing either RALP or ORRP were prospectively included to assess the extent of systemic response. Blood samples were collected before surgery (T1), at the time of prostatectomy (T2), at the time of wound closure (T3), and 12 h (T4), 24 h (T5), and 48 h (T6) after surgery, and assayed for interleukins (IL-6 and IL-10), C-reactive protein (CRP), and hemoglobin. A 2-sided p \\u0026lt; 0.05 was considered to indicate significance. Results: Baseline levels of IL-6, IL-10, and CRP were comparable in both arms of the study. IL-6 and IL-10 increased in both groups during surgery and reached maximum levels at 12 and 24 h after surgery. The RALP and RRP groups differed significantly at T2 (p = 0.009), T3 (p = 0.046), T5 (p = 0.05) and T6 (p = 0.0007) for IL-6, and at T3 (p = 0.05) and T4 (p = 0.05) for IL-10. CRP levels differed significantly at 48 h postoperative (p = 0.0053). The maximum levels of all 3 mediators in the RALP group were significantly lower than those in the open surgery group. Patients in the RALP group experienced less pain from day 2 to 4 according to the Visual Analog Scale (p \\u0026lt; 0.05). Conclusions: The study suggests that IL-6 and IL-10 are useful objective markers for surgical stress and that tissue trauma and activation of post-aggression metabolism seem to be less in RALP compared to ORRP."],["dc.identifier.doi","10.1159/000478027"],["dc.identifier.eissn","1423-0399"],["dc.identifier.issn","0042-1138"],["dc.identifier.pmid","28768259"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77099"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1423-0399"],["dc.relation.issn","0042-1138"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Prospective, Controlled Study of Invasiveness and Post-Aggression Metabolism in Patients Undergoing Robotic-Assisted Radical Prostatectomy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","613"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","The Prostate"],["dc.bibliographiccitation.lastpage","619"],["dc.bibliographiccitation.volume","76"],["dc.contributor.author","von Hardenberg, Jost"],["dc.contributor.author","Schwartz, Maike"],["dc.contributor.author","Werner, Thorsten"],["dc.contributor.author","Fuxius, Stefan"],["dc.contributor.author","Mueller, Markus"],["dc.contributor.author","Bolenz, Christian"],["dc.contributor.author","Weiss, Christel"],["dc.contributor.author","Heinrich, Elmar"],["dc.date.accessioned","2018-11-07T10:14:16Z"],["dc.date.available","2018-11-07T10:14:16Z"],["dc.date.issued","2016"],["dc.description.abstract","BACKGROUNDAbiraterone Acetate (AA) represents a highly effective androgen-receptor (AR) axis targeted agent. Treatment with AA in castration-resistant prostate cancer (CRPC) may partly mediate neuroendocrine differentiation (NED) as an escape mechanism, which may have implications for the choice of sequential therapy in CRPC. We evaluated how treatment with AA influences circulating neuromediators chromogranin A (CGA), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (Pro-GRP) in chemotherapy-naive CRPC patients. METHODSWe conducted an analysis in chemotherapy-naive CRPC patients with clinical or radiographic progression of disease. A total of 35 patients were included at five institutions between February 2013 and December 2014. Sixteen of them had received AA. Serum samples were obtained before a docetaxel-based chemotherapy and analyzed in a reference laboratory. Univariable and multivariable analyses were performed to test the influence of AA treatment, its duration of treatment, and other clinicopathological variables on circulating neuromediators. RESULTSCGA and NSE levels were above the upper limit of normal (ULN) in n=20 (57.1%) and n=13 (37.1%), respectively. Treatment with AA and duration of treatment were not associated with levels above the ULN (CGA and NSE) or higher levels (Pro-GRP) of neuromediators. CGA levels were associated with age (P=0.092), lymph node metastasis (P=0.014), duration of androgen deprivation therapy (ADT; P=0.083), and intake of proton pump inhibitors (P=0.069). Pro-GRP levels were significantly associated with PSA levels (P=0.002). On multivariate analysis, CGA levels above the ULN were significantly correlated with ADT (P=0.01) and intake of proton pump inhibitors (P=0.03). CONCLUSIONSCirculating neuromediators in chemotherapy-naive CRPC patients were elevated in a high percentage of patients. ADT was found to be a relevant NED driver in this cohort. Our results may imply that patients with CRPC after first-line treatment with AA in CRPC are not at a higher risk for developing NED. The major limitation of the study represents the one-time analysis of neuromediators. Larger studies with serial blood measurements or biopsy analysis before and after treatment are needed to confirm our results. Prostate 76:613-619, 2016. (c) 2016 Wiley Periodicals, Inc."],["dc.description.sponsorship","Sanofi-Aventis Deutschland GmbH"],["dc.identifier.doi","10.1002/pros.23152"],["dc.identifier.isi","000373932700001"],["dc.identifier.pmid","26779767"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40589"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1097-0045"],["dc.relation.issn","0270-4137"],["dc.title","Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naive castration-resistant prostate cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","414"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Urologia Internationalis"],["dc.bibliographiccitation.lastpage","421"],["dc.bibliographiccitation.volume","99"],["dc.contributor.author","von Hardenberg, Jost"],["dc.contributor.author","Schwartz, Maike"],["dc.contributor.author","Werner, Thorsten"],["dc.contributor.author","Fuxius, Stefan"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Worst, Thomas Stefan"],["dc.contributor.author","Nuhn, Philipp"],["dc.contributor.author","Bolenz, Christian"],["dc.contributor.author","Heinrich, Elmar"],["dc.date.accessioned","2020-12-10T18:37:48Z"],["dc.date.available","2020-12-10T18:37:48Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1159/000477943"],["dc.identifier.eissn","1423-0399"],["dc.identifier.issn","0042-1138"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77098"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]